NASDAQ: ONXX
Will ASCO Unlock Big Value in This Cancer Drug Class?
With the American Society of Clinical Oncology's annual meeting less than two weeks away, see what drug class could see big gains in the wake of new abstract data.3 Earnings Reports That Caught My Attention Last Week
Investors may have ignored these earnings reports, but I certainly did not!Good News for Cubist Pharmaceuticals - Analyst Blog
Good News for Cubist Pharmaceuticals - Analyst Blog